Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regencell Bioscience Holdings Ltd RGC

Healthcare
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates... see more

Recent & Breaking News (NDAQ:RGC)

    Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

    Business Wire May 16, 2022

    Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

    Business Wire February 16, 2022

    Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO

    Business Wire November 22, 2021

    Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index

    Business Wire November 22, 2021

    Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment

    Business Wire September 2, 2021

    Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option

    Business Wire August 20, 2021

    Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders

    Business Wire August 5, 2021

    Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

    Business Wire July 20, 2021

    Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering

    Business Wire July 15, 2021